Developer docs
API playgroundTry for free, no card

Search company profiles

RiAtlas

Full company profile

uuid0022und

Namestring
RiAtlas
Legal namestring
RiAtlas S.r.l.
Websiteurl
riatlas.it
Company typeenum
Private
Founded yearint
2017
Descriptiontext

RiAtlas S.r.l. is an Italian digital health company founded in September 2017 as an authorized spin-off of the University of Salerno. Operating from offices in Novi Velia, Fisciano, Penta, and Torre Annunziata, the company builds AI- and IoT-enabled Software Medical Devices for remote patient monitoring, clinical decision support, and continuity of care. Its core product, RiAtlas Healthcare, was upgraded to EU MDR Class IIa certification in late 2024, and is accompanied by RiAtlas Oncology (CE Class I, for cancer care pathways), NIA (a Class I telemonitoring solution for neurological diseases developed with NeMO Lab), and RiAtlas Clinical Trial (an add-on module for pharmaceutical companies). The underlying AI engine includes an Intelligent Classifier that maps patient state to the WHO ICF taxonomy, an incremental learning-based alerting system for early clinical risk detection, and context data visualization correlated over time, with two granted Italian patents protecting the core methods and HL7-FHIR interoperability underpinning the platform.

The company generates revenue through four streams: SaaS subscriptions for healthcare facilities, sale and licensing of certified medical device software (CE Class I and Class IIa), innovation and technology transfer consultancy services, and clinical trial management solutions for pharmaceutical companies. GTM is primarily direct enterprise sales to Italian public and private hospitals, pharmaceutical companies, and the national health system (SSN), supplemented by qualified SaaS provider status on the AgID Cloud Marketplace for public-sector procurement and event-driven demand generation through webinars and industry conferences. Named customers and validation partners include IRCCS Fondazione Pascale, Università della Campania Luigi Vanvitelli, NeMO Lab, and unnamed pharmaceutical companies. The company is structured as an Italian innovative startup (start-up innovativa) and PMI innovativa, has not disclosed any traditional venture capital or private equity funding, and has operated primarily on grant-based non-dilutive capital from EIT Health, Facebook AI Open Loop, Regione Campania, and LVenture Group.

Short descriptiontext

RiAtlas is an Italian digital health company and University of Salerno spin-off that builds EU MDR-certified AI and IoT Software Medical Devices for remote patient monitoring, oncology, neurological telemonitoring, and clinical trials, sold primarily to Italian hospitals and pharmaceutical companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersFisciano, Italy
HQ citystring
Fisciano
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital health software, remote patient monitoring, clinical decision support, medical device software, healthcare AI platforms
Industry1 code
PRIMARYHLACAPAK
Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
NAICS code2 codes
  • Custom Computer Programming Services541511
  • Computer Systems Design and Related Services54151
SIC code1 code
  • Services-Health Services8000
Product category
Digital Health Software (Remote Patient Monitoring & Clinical Decision Support)
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1SaaS Software as a Service
TypeSubscription Recurring
Description

Subscription-based SaaS model for healthcare facilities accessing RiAtlas Healthcare and other digital health solutions through cloud-based deployment.

riatlas.it
2Medical Device Software Sales
TypeOne Time License
Description

Sale/licensing of certified medical device software products (CE Class I and Class IIa) to healthcare providers and pharmaceutical companies.

riatlas.it
3Innovation and Technology Transfer Services
TypeProfessional Services
Description

Consultancy and services for design and development of digital health applications, implementation of medical software, and advanced tools for (big) health data analysis.

riatlas.it
4Clinical Trial Management Solutions
TypeSubscription Recurring
Description

Advanced clinical trial management solutions for pharmaceutical companies including Patient Reported Outcome tools and data analysis based on AI and IoT.

riatlas.it
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1RiAtlas Healthcare
Description

Digital health solution certified as Class IIa Medical Device Software for patient management, active monitoring and remote assistance for patients starting therapeutic care pathways with frequent hospital returns in continuity of care perspective.

riatlas.it
+3 more records
Core offering1 text field

RiAtlas develops and sells certified Software Medical Devices for remote patient monitoring and clinical decision support. Its flagship product, RiAtlas Healthcare, is an EU MDR Class IIa certified platform that enables management, active monitoring and remote assistance of patients transitioning from acute hospital care to therapeutic care pathways with frequent hospital readmissions. The platform combines a Patient Mobile App and Clinical Web App with an AI-based Intelligent Classifier that automatically classifies patient health status using the WHO ICF taxonomy and an Incremental Learning Alerting System for early clinical risk detection. RiAtlas also offers specialized variants (RiAtlas Oncology, NIA) and a clinical trial management module for pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 90% clinical concordance with physician decisions in oncology applications
+3 more records
Product overview1 text field

RiAtlas offers a portfolio of digital health solutions centered on AI-powered remote patient monitoring and clinical decision support. The core offering is RiAtlas Healthcare, a Class IIa certified Software Medical Device that provides remote patient monitoring through a Patient Mobile App and Clinical Web App, enhanced by an AI-based Intelligent Classifier for ICF health status classification and early clinical risk alerting. RiAtlas Oncology is a specialized oncology-focused variant of the platform for cancer patient care pathways. NIA is a modular neurological telemonitoring solution developed with NeMO Lab, covering patients with neuromuscular diseases. RiAtlas Clinical Trial is an add-on module for pharmaceutical companies to manage clinical studies with AI and IoT tools. Innovation and Technology Transfer Services and Business Intelligence represent additional professional service offerings. All solutions are built on a common AI engine using Incremental Learning, comply with HL7-FHIR interoperability standards, GDPR, OWASP, and are delivered via SaaS on the AgID Cloud Marketplace.

Product and service6 records
1RiAtlas Healthcare
CategoryDigital Health Software Medical Device
Description

RiAtlas Healthcare is an EU MDR Class IIa certified Software Medical Device for digital health, designed for the management, active monitoring and remote assistance of patients who, after an acute phase, begin a therapeutic care pathway with frequent hospital readmissions. The solution supports continuity of care and de-hospitalization through a Patient Mobile App and Clinical Web App, AI-based health status classification (WHO ICF), and an incremental learning alerting system for early clinical risk detection. It is intended for healthcare providers including public hospitals, oncology departments, and specialized clinics.

2RiAtlas Oncology
CategoryDigital Health Software Medical Device
Description

RiAtlas Oncology is a specialized digital health solution developed as a Software Medical Device for the integrated management of oncological patients' therapeutic pathways. It supports active monitoring, remote assistance, and AI-powered clinical decision-making for cancer care, including remote monitoring of COVID-19 patients in home isolation. The solution was clinically validated in collaboration with IRCCS Fondazione Pascale and Università degli Studi della Campania Luigi Vanvitelli, achieving over 90% clinical concordance with physician decisions.

3NIA
CategoryDigital Health Software Medical Device
Description

NIA is a modular Class I medical software device for the telemonitoring of patients with neurological diseases, developed in collaboration with NeMO Lab (NeMO Clinical Centre). It comprises a wearable device for vital parameters, a patient mobile app with neurological tests, a clinical web app, and an AI-based alert system. The solution targets patients with Parkinson's disease, stroke, neuromuscular diseases, and similar conditions requiring ongoing monitoring and care pathway management.

4RiAtlas Clinical Trial
CategoryClinical Trial Management Software
Description

RiAtlas Clinical Trial is an advanced clinical trial management solution for pharmaceutical companies. It leverages Patient Reported Outcome tools and AI/IoT-based data analysis to monitor therapy adherence and encourage active patient participation in their own treatment pathway, helping sponsors generate clinical evidence and improve trial efficiency.

5Innovation and Technology Transfer Services
CategoryProfessional Services
Description

Consultancy and services for the design and development of digital health applications, medical software implementation, and advanced tools for the analysis of (big) health data. The offering leverages RiAtlas's experience in healthcare innovation and digital transformation for clients including hospitals, healthcare facilities, and pharmaceutical companies.

6Business Intelligence
CategoryProfessional Services
Description

Design and development of Business Intelligence tools for advanced analysis of healthcare data and flows, including health status classification, clinical risk detection, and population stratification, supporting administrative and managerial decision-making in healthcare organizations.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1Facebook AI / Open Loop
Strategic tierCoreTypeStrategic or Co-development Partner
Description

RiAtlas was one of ten European companies chosen by Facebook AI to participate in the Open Loop global experimental governance program. The company contributed to creating evidence-based policy decisions for the European Commission on AI risk management, focusing on automated decision impact assessment tools for digital health.

riatlas.it
Strategic tierMinorTypeStrategic or Co-development Partner
Description

RiAtlas participated in Ericsson's innovation garages to stimulate cross-fertilization and experimentation in healthcare cybersecurity. The collaboration focused on developing GDPR-compliant blockchain technology for protecting sensitive healthcare data.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

RiAtlas maintains a point of contact at the Novartis Campus per l'Innovazione in Torre Annunziata, suggesting collaboration or presence within Novartis innovation ecosystem.

4AgID (Agenzia per l'Italia Digitale)
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Qualified SaaS provider on the Italian government's AgID Cloud Marketplace, enabling RiAtlas Healthcare to be procured by Italian public administration healthcare facilities. The qualification certifies compliance with security, reliability, and interoperability criteria.

riatlas.it
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint development of NIA, a telemonitoring solution for patients with neurological diseases. NeMO Lab is Italy's first technology hub for neuromuscular disease innovation, combining clinical center expertise with technology research groups and pharmaceutical industry partners.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical validation partner for RiAtlas Oncology solution in colorectal cancer patients. During COVID-19, the institute also used RiAtlas Oncology to create a remote monitoring system for coronavirus patients in home isolation.

7Università degli Studi della Campania Luigi Vanvitelli
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research partner in clinical validation of RiAtlas Oncology solution for oncology digital therapeutics and care pathway management.

oncology.riatlas.it
Strategic tierMinorTypeStrategic or Co-development Partner
Description

RiAtlas is a partner in the VENTIX project, co-funded under POR CAMPANIA FESR 2014/2020. The project aims to create an integrated system for home pulmonary ventilation treatment and remote monitoring of complex COPD patients.

Strategic tierMinorTypeGTM or Marketing Partner
Description

RiAtlas was selected among innovative Italian SMEs for the 'Reach The Goals' report dedicated to companies operating in UN Sustainable Development Goals areas, helping increase visibility among impact investors and partners.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Market position
Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RiAtlas

Digital Health Software (Remote Patient Monitoring & Clinical Decision Support)riatlas.it

RiAtlas is an Italian digital health company and University of Salerno spin-off that builds EU MDR-certified AI and IoT Software Medical Devices for remote patient monitoring, oncology, neurological telemonitoring, and clinical trials, sold primarily to Italian hospitals and pharmaceutical companies.

What RiAtlas does

RiAtlas S.r.l. is an Italian digital health company founded in September 2017 as an authorized spin-off of the University of Salerno. Operating from offices in Novi Velia, Fisciano, Penta, and Torre Annunziata, the company builds AI- and IoT-enabled Software Medical Devices for remote patient monitoring, clinical decision support, and continuity of care. Its core product, RiAtlas Healthcare, was upgraded to EU MDR Class IIa certification in late 2024, and is accompanied by RiAtlas Oncology (CE Class I, for cancer care pathways), NIA (a Class I telemonitoring solution for neurological diseases developed with NeMO Lab), and RiAtlas Clinical Trial (an add-on module for pharmaceutical companies). The underlying AI engine includes an Intelligent Classifier that maps patient state to the WHO ICF taxonomy, an incremental learning-based alerting system for early clinical risk detection, and context data visualization correlated over time, with two granted Italian patents protecting the core methods and HL7-FHIR interoperability underpinning the platform.

The company generates revenue through four streams: SaaS subscriptions for healthcare facilities, sale and licensing of certified medical device software (CE Class I and Class IIa), innovation and technology transfer consultancy services, and clinical trial management solutions for pharmaceutical companies. GTM is primarily direct enterprise sales to Italian public and private hospitals, pharmaceutical companies, and the national health system (SSN), supplemented by qualified SaaS provider status on the AgID Cloud Marketplace for public-sector procurement and event-driven demand generation through webinars and industry conferences. Named customers and validation partners include IRCCS Fondazione Pascale, Università della Campania Luigi Vanvitelli, NeMO Lab, and unnamed pharmaceutical companies. The company is structured as an Italian innovative startup (start-up innovativa) and PMI innovativa, has not disclosed any traditional venture capital or private equity funding, and has operated primarily on grant-based non-dilutive capital from EIT Health, Facebook AI Open Loop, Regione Campania, and LVenture Group.

RiAtlas firmographics

Firmographics
Name
RiAtlas
Legal name
RiAtlas S.r.l.
Website
https://riatlas.it
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
RiAtlas is an Italian digital health company and University of Salerno spin-off that builds EU MDR-certified AI and IoT Software Medical Devices for remote patient monitoring, oncology, neurological telemonitoring, and clinical trials, sold primarily to Italian hospitals and pharmaceutical companies.
Ownership category
akta.pro rank

RiAtlas industry classification

Industry
Product category
Digital Health Software (Remote Patient Monitoring & Clinical Decision Support)
NAICS
Custom Computer Programming Services (541511), Computer Systems Design and Related Services (54151)
SIC
Services-Health Services (8000)
akta.pro industry
PRIMARYHLACAPAK
Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring

Keywords

  • Digital health software
  • Remote patient monitoring
  • Clinical decision support
  • Medical device software
  • Healthcare AI platforms

Where RiAtlas is headquartered

Location

Headquarters

HQ city
Fisciano
HQ country
Italy
HQ region
Europe

Offices4 records

Markets served

RiAtlas business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. SaaS Software as a Service: Subscription-based SaaS model for healthcare facilities accessing RiAtlas Healthcare and other digital health solutions through cloud-based deployment.
  2. Medical Device Software Sales: Sale/licensing of certified medical device software products (CE Class I and Class IIa) to healthcare providers and pharmaceutical companies.
  3. Innovation and Technology Transfer Services: Consultancy and services for design and development of digital health applications, implementation of medical software, and advanced tools for (big) health data analysis.
  4. Clinical Trial Management Solutions: Advanced clinical trial management solutions for pharmaceutical companies including Patient Reported Outcome tools and data analysis based on AI and IoT.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

RiAtlas product offering

Product offering

Core offering

RiAtlas develops and sells certified Software Medical Devices for remote patient monitoring and clinical decision support. Its flagship product, RiAtlas Healthcare, is an EU MDR Class IIa certified platform that enables management, active monitoring and remote assistance of patients transitioning from acute hospital care to therapeutic care pathways with frequent hospital readmissions. The platform combines a Patient Mobile App and Clinical Web App with an AI-based Intelligent Classifier that automatically classifies patient health status using the WHO ICF taxonomy and an Incremental Learning Alerting System for early clinical risk detection. RiAtlas also offers specialized variants (RiAtlas Oncology, NIA) and a clinical trial management module for pharmaceutical companies.

Product overview

RiAtlas offers a portfolio of digital health solutions centered on AI-powered remote patient monitoring and clinical decision support. The core offering is RiAtlas Healthcare, a Class IIa certified Software Medical Device that provides remote patient monitoring through a Patient Mobile App and Clinical Web App, enhanced by an AI-based Intelligent Classifier for ICF health status classification and early clinical risk alerting. RiAtlas Oncology is a specialized oncology-focused variant of the platform for cancer patient care pathways. NIA is a modular neurological telemonitoring solution developed with NeMO Lab, covering patients with neuromuscular diseases. RiAtlas Clinical Trial is an add-on module for pharmaceutical companies to manage clinical studies with AI and IoT tools. Innovation and Technology Transfer Services and Business Intelligence represent additional professional service offerings. All solutions are built on a common AI engine using Incremental Learning, comply with HL7-FHIR interoperability standards, GDPR, OWASP, and are delivered via SaaS on the AgID Cloud Marketplace.

Differentiator

Problem solved

Functional benefit

Brands

  • RiAtlas Healthcare: Digital health solution certified as Class IIa Medical Device Software for patient management, active monitoring and remote assistance for patients starting therapeutic care pathways with frequent hospital returns in continuity of care perspective.
  • RiAtlas Oncology
  • RiAtlas Clinical Trial
  • NIA

Products and services

  • RiAtlas Healthcare RiAtlas Healthcare is an EU MDR Class IIa certified Software Medical Device for digital health, designed for the management, active monitoring and remote assistance of patients who, after an acute phase, begin a therapeutic care pathway with frequent hospital readmissions. The solution supports continuity of care and de-hospitalization through a Patient Mobile App and Clinical Web App, AI-based health status classification (WHO ICF), and an incremental learning alerting system for early clinical risk detection. It is intended for healthcare providers including public hospitals, oncology departments, and specialized clinics.
  • RiAtlas Oncology RiAtlas Oncology is a specialized digital health solution developed as a Software Medical Device for the integrated management of oncological patients' therapeutic pathways. It supports active monitoring, remote assistance, and AI-powered clinical decision-making for cancer care, including remote monitoring of COVID-19 patients in home isolation. The solution was clinically validated in collaboration with IRCCS Fondazione Pascale and Università degli Studi della Campania Luigi Vanvitelli, achieving over 90% clinical concordance with physician decisions.
  • NIA NIA is a modular Class I medical software device for the telemonitoring of patients with neurological diseases, developed in collaboration with NeMO Lab (NeMO Clinical Centre). It comprises a wearable device for vital parameters, a patient mobile app with neurological tests, a clinical web app, and an AI-based alert system. The solution targets patients with Parkinson's disease, stroke, neuromuscular diseases, and similar conditions requiring ongoing monitoring and care pathway management.
  • RiAtlas Clinical Trial RiAtlas Clinical Trial is an advanced clinical trial management solution for pharmaceutical companies. It leverages Patient Reported Outcome tools and AI/IoT-based data analysis to monitor therapy adherence and encourage active patient participation in their own treatment pathway, helping sponsors generate clinical evidence and improve trial efficiency.
  • Innovation and Technology Transfer Services Consultancy and services for the design and development of digital health applications, medical software implementation, and advanced tools for the analysis of (big) health data. The offering leverages RiAtlas's experience in healthcare innovation and digital transformation for clients including hospitals, healthcare facilities, and pharmaceutical companies.
  • Business Intelligence Design and development of Business Intelligence tools for advanced analysis of healthcare data and flows, including health status classification, clinical risk detection, and population stratification, supporting administrative and managerial decision-making in healthcare organizations.

Quantifiable outcome

  • Over 90% clinical concordance with physician decisions in oncology applications
  • +3 more outcomes

Companies that use RiAtlas

Customer profile

Named customers4 records

Segments5 records

Ideal customer profiles3 records

RiAtlas technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

RiAtlas partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • Facebook AI / Open LoopcoreStrategic or Co-development PartnerRiAtlas was one of ten European companies chosen by Facebook AI to participate in the Open Loop global experimental governance program. The company contributed to creating evidence-based policy decisions for the European Commission on AI risk management, focusing on automated decision impact assessment tools for digital health.
  • EricssonminorStrategic or Co-development PartnerRiAtlas participated in Ericsson's innovation garages to stimulate cross-fertilization and experimentation in healthcare cybersecurity. The collaboration focused on developing GDPR-compliant blockchain technology for protecting sensitive healthcare data.
  • NovartisminorChannel Partner/ Reseller/ DistributorRiAtlas maintains a point of contact at the Novartis Campus per l'Innovazione in Torre Annunziata, suggesting collaboration or presence within Novartis innovation ecosystem.
  • AgID (Agenzia per l'Italia Digitale)coreChannel Partner/ Reseller/ DistributorQualified SaaS provider on the Italian government's AgID Cloud Marketplace, enabling RiAtlas Healthcare to be procured by Italian public administration healthcare facilities. The qualification certifies compliance with security, reliability, and interoperability criteria.
  • NeMO Lab (Centro Clinico Nemo)coreStrategic or Co-development PartnerJoint development of NIA, a telemonitoring solution for patients with neurological diseases. NeMO Lab is Italy's first technology hub for neuromuscular disease innovation, combining clinical center expertise with technology research groups and pharmaceutical industry partners.
  • Istituto Nazionale Tumori – IRCCS Fondazione PascalecoreStrategic or Co-development PartnerClinical validation partner for RiAtlas Oncology solution in colorectal cancer patients. During COVID-19, the institute also used RiAtlas Oncology to create a remote monitoring system for coronavirus patients in home isolation.
  • Università degli Studi della Campania Luigi VanvitellicoreStrategic or Co-development PartnerAcademic research partner in clinical validation of RiAtlas Oncology solution for oncology digital therapeutics and care pathway management.
  • AQUA BIOTECHminorStrategic or Co-development PartnerRiAtlas is a partner in the VENTIX project, co-funded under POR CAMPANIA FESR 2014/2020. The project aims to create an integrated system for home pulmonary ventilation treatment and remote monitoring of complex COPD patients.
  • CariploFactoryminorGTM or Marketing PartnerRiAtlas was selected among innovative Italian SMEs for the 'Reach The Goals' report dedicated to companies operating in UN Sustainable Development Goals areas, helping increase visibility among impact investors and partners.

Scale indicators3 records

Recent moves7 records

Expansion highlights2 records

RiAtlas competitors and assessment

Company assessment

Market position

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

RiAtlas social profiles

Digital presence

RiAtlas compliance and trust

Trust signal

Compliance7 records

RiAtlas financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RiAtlas leadership team

Management profile

Number of profiles

Profiles3 records

RiAtlas funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RiAtlas M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RiAtlas

What does RiAtlas do?

RiAtlas develops and sells certified Software Medical Devices for remote patient monitoring and clinical decision support. Its flagship product, RiAtlas Healthcare, is an EU MDR Class IIa certified platform that enables management, active monitoring and remote assistance of patients transitioning from acute hospital care to therapeutic care pathways with frequent hospital readmissions. The platform combines a Patient Mobile App and Clinical Web App with an AI-based Intelligent Classifier that automatically classifies patient health status using the WHO ICF taxonomy and an Incremental Learning Alerting System for early clinical risk detection. RiAtlas also offers specialized variants (RiAtlas Oncology, NIA) and a clinical trial management module for pharmaceutical companies.

Is RiAtlas a public or private company?

RiAtlas is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was RiAtlas founded?

RiAtlas was founded in 2017. It employs 1 to 10 people.

Where is RiAtlas based?

RiAtlas is headquartered in Fisciano, Italy, in the Europe region.

How does RiAtlas make money?

Four revenue lines are on record. SaaS Software as a Service is the primary driver. The others are medical Device Software Sales, innovation and Technology Transfer Services and clinical Trial Management Solutions.

Does RiAtlas have an API?

No public API is recorded for RiAtlas.

What industry is RiAtlas in?

RiAtlas's product category is Digital Health Software (Remote Patient Monitoring & Clinical Decision Support). Its primary akta.pro industry code is HLACAPAK, Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices). Its NAICS code is 541511 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales